Journal of the American Society of Hypertension
Volume 3, Issue 5 , Pages 291-294 , September 2009

Inherent inaccuracies and potential utility of race/ethnicity labeling in the treatment of hypertension

  • Barry J. Materson, MD, MBA

      Affiliations

    • Corresponding Author InformationCorresponding author: Barry J. Materson, MD, MBA, University of Miami (D-54), P. O. Box 016960, Miami, Florida 33101. Tel: 305-243-7221; fax: 305-243-9902.
    • ,
  • Eileen M. Bernal, BS

Received 7 August 2009 ,Accepted 7 August 2009.

References 

  1. Root M. The use of race in medicine as a proxy for genetic differences. Philos Sci. 2003;70:1173–1183
  2. Huth EJ. Identifying ethnicity in medical papers. In:  Ferrante J,  Brown P editor. The social construction of race and ethnicity in the United States. New York, New York: Longman; 1998;p. 435–439
  3. Torres JB, Kittles RA. The relationship between “race” and genetics in biomedical research. Curr Hypertens Reports. 2007;9:196–201
  4. Davis FJ. Who is Black?. One nation's definition. Tenth anniversary edition. University Park, Pennsylvania: Pennsylvania State University Press; 2001;
  5. Ferdinand KC, Ferdinand DP. Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Rev Cardiovasc Ther. 2008;10:1357–1366
  6. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. JAMA. 1982;248:1996–2003
  7. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol. 1983;52:1230–1237
  8. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14:97S–101S
  9. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Int Med. 1984;144:1947–1953
  10. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914–921
  11. Materson BJ, Reda DJ. Correction: single-drug therapy for hypertension in men. N Engl J Med. 1994;330:1689
  12. Materson BJ, Reda DJ, Cushman WC for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens. 1995;8:189–192
  13. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:1168–1172
  14. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook E, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients. The quinapril titration interval management evaluation trial. Hypertension. 2004;43:1202–1207
  15. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in U.S. veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624–1630
  16. Kountz DS. Hypertension in ethnic populations: tailoring treatments. Clinical Cornerstone. 2004;6:39–48
  17. Yancy G. Who is White?: Latinos, Asians, and the new black/nonblack divide. Boulder, Colorado: Lynne Rienner; 2003;
  18. Salari K, Choudhry S, Tang H, Naqvi M, Lind D, Avila PC, et al. Genetic admixture and asthma-related phenotypes in Mexican American and Puerto Rican asthmatics. Genetic Epidemiology. 2005;29:76–86
  19. Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, et al. Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2007;50:854–861
  20. Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SDJ. Self-reported skin color, genomic ancestry, and the distribution of GST polymorphisms. Pharmacogenet Genomics. 2007;17:765–771
  21. Su T-C, Hwang L-C, You S-L, Chen C-J. Ethnic variation in hypertension prevalence of women in Taiwan. J Hum Hypertens. 2009;23:160–167
  22. The China Salt Substitute Study Collaborative Group. Salt substitution: a low-cost strategy for blood pressure control among rural Chinese. A randomized controlled trial. J Hypertens. 2007;25:2011–2018
  23. Liu L, Wang JG, Gong L, Liu G, Staessen JA the Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823–1829
  24. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141–144
  25. Sharma S. Hypertension and cardiovascular disease in South Asia: no end in sight. J Am Soc Hypertens. 2008;2:125–130
  26. Jafar TH, Levey AS, Jafary FH, White F, Gul A, Rahbar MH, et al. Ethnic subgroup differences in hypertension in Pakistan. J Hypertens. 2003;21:905–912

 Conflict of interest: none.

PII: S1933-1711(09)00101-6

doi: 10.1016/j.jash.2009.08.001

Journal of the American Society of Hypertension
Volume 3, Issue 5 , Pages 291-294 , September 2009

Article Tools

* Image Usage & Resolution